to fully acquire

LONDON: Haleon plc has entered into an agreement to acquire the remaining 12% equity interest in its Chinese over-the-counter (OTC) joint venture, Tianjin TSKF Pharmaceutical Co., Ltd., from partner Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, the company announced Tuesday. The acquisition, valued at approximately 1.623 billion renminbi (£0.2 billion), follows Haleon’s purchase of a…